{"id":60148,"date":"2026-03-20T13:24:17","date_gmt":"2026-03-20T05:24:17","guid":{"rendered":"https:\/\/flcube.com\/?p=60148"},"modified":"2026-03-20T13:24:18","modified_gmt":"2026-03-20T05:24:18","slug":"belief-biomed-secures-macao-approval-for-bbm-h901-chinas-first-hemophilia-b-gene-therapy-expands-to-greater-china-with-takeda","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60148","title":{"rendered":"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China&#8217;s First Hemophilia B Gene Therapy Expands to Greater China with Takeda"},"content":{"rendered":"\n<p><strong>Belief BioMed<\/strong> announced <strong>marketing approval<\/strong> from the <strong>Pharmaceutical Administration Bureau of Macao Special Administrative Region<\/strong> for <strong>dalnacogene ponparvovec (BBM\u2011H901)<\/strong>, its <strong>AAV\u2011based gene therapy for moderate\u2011to\u2011severe hemophilia B<\/strong>, extending the commercial footprint of <strong>China&#8217;s first approved hemophilia B gene therapy<\/strong> across <strong>Greater China through exclusive commercialization partnership with Takeda China<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Dalnacogene ponparvovec (BBM\u2011H901)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Belief BioMed (China\u2011origin)<\/td><\/tr><tr><td><strong>New Approval<\/strong><\/td><td>Macao SAR, China<\/td><\/tr><tr><td><strong>Prior Approval<\/strong><\/td><td><strong>NMPA (China mainland)<\/strong> \u2013 April 2025 (<strong>first approved hemophilia B gene therapy in China<\/strong>)<\/td><\/tr><tr><td><strong>Commercialization Partner<\/strong><\/td><td>Takeda China<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China, Hong Kong, Macao<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism-of-action\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology:<\/strong> <strong>rAAV5 (recombinant adeno\u2011associated virus serotype 5)<\/strong> gene therapy<\/li>\n\n\n\n<li><strong>Vector Engineering:<\/strong> <strong>Liver\u2011tropic<\/strong> rAAV vector optimized for hepatocyte transduction<\/li>\n\n\n\n<li><strong>Gene Payload:<\/strong> <strong>Optimized human Factor IX gene<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n\n\n\n<li>AAV vector delivers Factor IX gene to <strong>liver cells<\/strong><\/li>\n\n\n\n<li>Host cell transcription machinery drives <strong>continuous Factor IX production<\/strong><\/li>\n\n\n\n<li>Secreted Factor IX enters bloodstream \u2192 <strong>restores procoagulant activity<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Single\u2011dose potential for long\u2011term\/hemostatic Factor IX levels vs. lifelong prophylactic factor IX infusions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercialization-structure\">Commercialization Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Belief BioMed<\/th><th>Takeda China<\/th><\/tr><\/thead><tbody><tr><td><strong>Development &amp; Manufacturing<\/strong><\/td><td>Origin asset; gene therapy platform IP<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>NMPA, Macao, Hong Kong filings<\/td><td>Leverages Takeda&#8217;s regional regulatory expertise<\/td><\/tr><tr><td><strong>Commercial Execution<\/strong><\/td><td>\u2013<\/td><td><strong>Exclusive<\/strong> commercialization rights Greater China<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>\u2013<\/td><td>Takeda&#8217;s hemophilia franchise (Advate, Adynovate) infrastructure and KOL relationships<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hemophilia B Market Dynamics:<\/strong> China ~15,000\u201120,000 hemophilia B patients; &lt;5% receive prophylactic factor IX replacement due to cost\/availability; gene therapy addressable market estimated <strong>US$300\u2011500 million annually<\/strong> in Greater China at premium pricing (US$2\u20113 million per treatment).<\/li>\n\n\n\n<li><strong>BBM\u2011H901 Competitive Position:<\/strong> First\u2011mover advantage in China vs. global gene therapies (CSL Behring&#8217;s Hemgenix \u2013 approved US\/EU 2022\u20112023, not yet China\u2011approved); Takeda partnership provides commercial infrastructure that Belief BioMed lacks as development\u2011stage biotech.<\/li>\n\n\n\n<li><strong>Macao Approval Strategic Value:<\/strong> Macao as <strong>regulatory reference<\/strong> for Hong Kong approval (expected H2 2026); Greater China commercial launch enables consolidated market access strategy vs. fragmented national approvals; potential for Macao\u2011based treatment tourism initially.<\/li>\n\n\n\n<li><strong>Takeda Gene Therapy Strategy:<\/strong> BBM\u2011H901 adds to Takeda&#8217;s rare disease gene therapy portfolio (acquired Shire legacy); leverages existing hemophilia sales force; partnership model de\u2011risks development costs while retaining commercial upside in high\u2011growth China market.<\/li>\n\n\n\n<li><strong>Manufacturing &amp; Access Considerations:<\/strong> AAV gene therapy manufacturing capacity constrained globally; Belief BioMed&#8217;s China\u2011based production (vs. import dependency) supports pricing flexibility and supply security; reimbursement negotiations with national\/municipal insurance critical for volume adoption given high one\u2011time cost.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercialization timelines, market penetration expectations, and partnership performance for BBM\u2011H901 in Greater China. Actual results may differ due to reimbursement challenges, manufacturing scale\u2011up constraints, and competitive gene therapy developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[465,66,15,345],"class_list":["post-60148","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-belief-biomed","tag-gene-therapy","tag-product-approvals","tag-takeda"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China&#039;s First Hemophilia B Gene Therapy Expands to Greater China with Takeda - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region for dalnacogene ponparvovec (BBM\u2011H901), its AAV\u2011based gene therapy for moderate\u2011to\u2011severe hemophilia B, extending the commercial footprint of China&#039;s first approved hemophilia B gene therapy across Greater China through exclusive commercialization partnership with Takeda China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60148\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China&#039;s First Hemophilia B Gene Therapy Expands to Greater China with Takeda\" \/>\n<meta property=\"og:description\" content=\"Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region for dalnacogene ponparvovec (BBM\u2011H901), its AAV\u2011based gene therapy for moderate\u2011to\u2011severe hemophilia B, extending the commercial footprint of China&#039;s first approved hemophilia B gene therapy across Greater China through exclusive commercialization partnership with Takeda China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60148\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-20T05:24:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T05:24:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60148#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60148\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China&#8217;s First Hemophilia B Gene Therapy Expands to Greater China with Takeda\",\"datePublished\":\"2026-03-20T05:24:17+00:00\",\"dateModified\":\"2026-03-20T05:24:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60148\"},\"wordCount\":478,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Belief BioMed\",\"Gene therapy\",\"Product approvals\",\"Takeda\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60148#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60148\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60148\",\"name\":\"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China's First Hemophilia B Gene Therapy Expands to Greater China with Takeda - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-20T05:24:17+00:00\",\"dateModified\":\"2026-03-20T05:24:18+00:00\",\"description\":\"Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region for dalnacogene ponparvovec (BBM\u2011H901), its AAV\u2011based gene therapy for moderate\u2011to\u2011severe hemophilia B, extending the commercial footprint of China's first approved hemophilia B gene therapy across Greater China through exclusive commercialization partnership with Takeda China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60148#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60148\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60148#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China&#8217;s First Hemophilia B Gene Therapy Expands to Greater China with Takeda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China's First Hemophilia B Gene Therapy Expands to Greater China with Takeda - Insight, China&#039;s Pharmaceutical Industry","description":"Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region for dalnacogene ponparvovec (BBM\u2011H901), its AAV\u2011based gene therapy for moderate\u2011to\u2011severe hemophilia B, extending the commercial footprint of China's first approved hemophilia B gene therapy across Greater China through exclusive commercialization partnership with Takeda China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60148","og_locale":"en_US","og_type":"article","og_title":"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China's First Hemophilia B Gene Therapy Expands to Greater China with Takeda","og_description":"Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region for dalnacogene ponparvovec (BBM\u2011H901), its AAV\u2011based gene therapy for moderate\u2011to\u2011severe hemophilia B, extending the commercial footprint of China's first approved hemophilia B gene therapy across Greater China through exclusive commercialization partnership with Takeda China.","og_url":"https:\/\/flcube.com\/?p=60148","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-20T05:24:17+00:00","article_modified_time":"2026-03-20T05:24:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60148#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60148"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China&#8217;s First Hemophilia B Gene Therapy Expands to Greater China with Takeda","datePublished":"2026-03-20T05:24:17+00:00","dateModified":"2026-03-20T05:24:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60148"},"wordCount":478,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Belief BioMed","Gene therapy","Product approvals","Takeda"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60148#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60148","url":"https:\/\/flcube.com\/?p=60148","name":"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China's First Hemophilia B Gene Therapy Expands to Greater China with Takeda - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-20T05:24:17+00:00","dateModified":"2026-03-20T05:24:18+00:00","description":"Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region for dalnacogene ponparvovec (BBM\u2011H901), its AAV\u2011based gene therapy for moderate\u2011to\u2011severe hemophilia B, extending the commercial footprint of China's first approved hemophilia B gene therapy across Greater China through exclusive commercialization partnership with Takeda China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60148#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60148"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60148#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Belief BioMed Secures Macao Approval for BBM\u2011H901 \u2013 China&#8217;s First Hemophilia B Gene Therapy Expands to Greater China with Takeda"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60148"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60148\/revisions"}],"predecessor-version":[{"id":60150,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60148\/revisions\/60150"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}